HEC-151

HEC-151 is a long-acting basal insulin analogue developed by Sunshine Lake Pharma Co., Ltd. for the treatment of diabetes mellitus. It is being developed as a biosimilar to insulin degludec (Tresiba). The drug functions by binding to the insulin receptor, thereby facilitating glucose uptake into muscle and fat cells and inhibiting glucose output from the liver. Its ultra-long duration of action is achieved through the formation of soluble multi-hexamers upon subcutaneous injection, which creates a depot for slow and steady absorption into the systemic circulation, providing a stable glucose-lowering effect for over 42 hours.

Other names

insulin degludec biosimilar